NDA Consultancy and ABPI Benefit From Former NICE Grandee Longson’s HTA Knowhow
Executive Summary
Pharma companies will be able to benefit from Carole Longson’s considerable expertise on two fronts. After 18 years in top-level roles at UK HTA body NICE, Longson is joining international consultancy group NDA as well as the UK industry association, the ABPI.
You may also be interested in...
Veteran NICE Director Longson Leaves UK HTA Body For New Role At ABPI
The UK R&D-based industry body will benefit from Carole Longson’s huge expertise in health technology assessment-related matters. Longson is leaving NICE after 17 years to take up the new role of chief scientific officer at the Association of the British Pharmaceutical Industry.
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.